Biogen Analysts Lower Their Forecasts After Q4 Results

1. Biogen's Q4 adjusted EPS beat expectations at $3.44, up 17%. 2. Sales reached $2.46 billion, exceeding consensus by $60 million. 3. Multiple sclerosis revenue fell 8%, highlighting ongoing challenges. 4. 2025 EPS forecast dropped, with anticipated revenue decline. 5. Analysts adjusted price targets downward, maintaining Buy ratings.